NASDAQ:LPCN Lipocine Q3 2025 Earnings Report $2.12 0.00 (-0.14%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lipocine EPS ResultsActual EPS-$0.59Consensus EPS -$0.56Beat/MissMissed by -$0.03One Year Ago EPSN/ALipocine Revenue ResultsActual Revenue$0.11 millionExpected Revenue$0.24 millionBeat/MissMissed by -$123.43 thousandYoY Revenue GrowthN/ALipocine Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsLipocine's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Lipocine Earnings HeadlinesHC Wainwright Reaffirms "Neutral" Rating for Lipocine (NASDAQ:LPCN)September 23 at 2:03 AM | americanbankingnews.comHC Wainwright Weighs in on Lipocine FY2027 EarningsSeptember 22 at 7:29 AM | americanbankingnews.comThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the layers beneath the AI boom - GPU hardware and financing, managed AI infrastructure, high-density data centers, and edge computing. The company points to an AI infrastructure market that could surpass 800 billion dollars by 2030, with a planned 20 MW Chicago data center targeting revenue in Q2 2027. A non-binding collaboration with Quantum eMotion is exploring quantum-security integration for GPU clusters, with a pilot targeted for 2026. Execution risks remain, but the setup connects compute demand, infrastructure buildout, and next-generation security.September 24 at 1:00 AM | Trading Wire (Ad)Lipocine (NASDAQ:LPCN) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?September 15, 2026 | americanbankingnews.comLipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionSeptember 14, 2026 | prnewswire.comLipocine Updates Sales Agreement Fee Structure with A.G.P.September 11, 2026 | tipranks.comSee More Lipocine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lipocine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipocine and other key companies, straight to your email. Email Address About LipocineLipocine (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients. Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S. Food and Drug Administration for adult men with testosterone deficiency associated with underlying medical conditions. The company has also advanced additional oral therapies in areas including metabolic and liver diseases, central nervous system disorders, and women’s health. Founded in 2008, Lipocine has primarily focused on research, clinical development, regulatory activities, and partnerships to advance its product candidates in the United States and other potential markets. Its development programs and commercial strategy may evolve as the company evaluates clinical data, regulatory requirements, and licensing or commercialization opportunities.View Lipocine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
